A 483 observation, a Notified Body major nonconformity, or a stage-two MDSAP finding all share the same underlying demand: prove that the corrective action reaches root cause and that the system will not fail the same way again. Under FDA QMSR, the stakes rose, because the management review, internal audit, and supplier audit records that were exempt from inspection under the withdrawn 21 CFR 820.180(c) exemption are now open to FDA. A remediation that looks complete on paper but leaves the underlying record trail weak is a finding waiting to be re-cited.
We remediate the quality subsystems that regulators scrutinize most, against the exact framework the finding was raised under, so the corrected system satisfies the body that raised it.
What we remediate
- Audit and inspection findings. FDA 483 observations, warning letter commitments, Notified Body nonconformities, and MDSAP findings, driven from response through verified closure.
- CAPA remediation. Review of existing CAPAs for root-cause adequacy, remediation of ineffective corrective actions, and a defensible effectiveness-check framework.
- Documentation gaps. Procedures, records, and technical documentation that do not meet the applicable standard or that reference superseded regulatory structure.
- Supplier controls. Qualification, monitoring, quality agreements, and outsourced-process controls, one of the most frequently cited areas in MDSAP and EU MDR audits.
- Complaint handling. Complaint intake, investigation, and vigilance and reporting pathways.
- Management review. Review inputs, decision records, and the action-item closure trail now exposed to FDA inspection.
- Internal audit programs. Program design, auditor qualification, and audit records rewritten to withstand inspection rather than expose the company.
- FDA QMSR transition. Remediation of internal audit programs, SOPs, and training records still built on legacy QSR references.
- ISO 13485 and MDSAP deficiencies. Clause-level correction of quality management system gaps against ISO 13485 and all five MDSAP jurisdictions.
What you receive
- A remediation plan mapping each finding or gap to a corrective action, an owner, and a target date
- Root-cause analysis for each systemic finding
- Revised procedures, records, and documentation
- CAPA development or remediation with closure verification
- An effectiveness-check framework to demonstrate the fix held
- A written summary suitable for Management Review and for your regulatory response
Typical engagement format
Remediation begins with a scoping review of the findings and the affected subsystems, followed by a prioritized plan set against your regulatory commitment dates. A single-subsystem remediation typically runs three to six weeks; a broad remediation across several subsystems following a 483 or a major nonconformity generally runs two to four months. Most work is performed remotely, with on-site support scoped in where a finding requires direct process observation. Where a follow-up inspection or audit will verify closure, we prepare your team for that engagement and structure the evidence that demonstrates effective corrective action.
Frequently asked questions
How long does a QMS remediation engagement take?
It depends on the scope and the severity of the findings. A focused remediation of a single subsystem, such as CAPA or supplier controls, typically runs three to six weeks. A broad remediation following an FDA 483 or a Notified Body major nonconformity, spanning several subsystems, generally runs two to four months. Timelines are set against your regulatory commitment dates, and we work backward from any response deadline you are already under.
What standards and regulations do you remediate against?
FDA QMSR (21 CFR Part 820 as harmonized with ISO 13485:2016), ISO 13485, MDSAP across all five jurisdictions, and EU MDR. Remediation is performed against the specific framework your audit or inspection was conducted under, so the corrected system satisfies the body that raised the finding.
Can remediation be performed remotely?
Most remediation work is performed remotely, including record review, root-cause analysis, procedure revision, and CAPA development. On-site support is available where a finding requires direct observation of a process or hands-on work with your team, and is scoped into the engagement when needed.
Can you support us through an FDA inspection or Notified Body audit while remediation is underway?
Yes. Remediation frequently runs in parallel with an active regulatory commitment. We can prepare your team for the follow-up inspection or audit, structure the evidence that demonstrates effective corrective action, and support you through the auditor engagement that verifies closure.
Do you review our existing CAPAs, or only open new ones?
Both. We review existing CAPAs for root-cause adequacy and effective closure, because a CAPA closed without addressing root cause reopens as a repeat finding and, under QMSR, sits in a record FDA can now inspect. Where existing corrective actions are sound, we verify and document that; where they are not, we remediate them properly.
Facing a finding, or want to close gaps before the auditor does?
Send the details of your situation and we will scope a remediation plan against your regulatory commitment dates. If you are working to a 483 response deadline or a Notified Body closure date, tell us the date and we will work backward from it.
Request a Remediation Discussion →Related services
QMS remediation connects to the rest of the quality system. Related work includes FDA QMSR readiness, internal and supplier audits, CAPA and quality system improvement, risk management to ISO 14971, and fractional quality leadership. For the full range, see our quality and regulatory solutions, or read the blog for background on what FDA can now inspect under QMSR.